Partner with us and leverage our technology for the development of the next wave of superior protein conjugates and Antibody-Drug-Conjugates! Looking to fast track your development of next generation bioconjugates, staying ahead of your competitors? With the complete freedom to choose where on the protein, we conjugate and optimize for: • Stability, • Aggregation, • Superior efficacy, • Therapeutic window ... and more! The process is simple! 1. Get in touch with us (message us here or visit our website). 2. After you let us know about your protein of interest, we produce different site-specific conjugate versions for you. 3. They are shipped either to you or your CRO. 4. You collect the data you need. 5. Go or no-go decision.
| Website | https://valanx.bio |
| Employees | 14 (14 on RocketReach) |
| Founded | 2017 |
| Address | Plöcking 1 3400, Klosterneuburg, Lower Austria 3400, AT |
| Technologies |
JavaScript
,
HTML
,
PHP
+15 more
(view full list)
|
| Industry | Biotechnology, Bioconjugation, Science and Engineering, Site-specific conjugation, Medical, PEGylation, Health Care, Pharmaceutical, Research and Development |
| Keywords | Antibody Drug Conjugates, Adc, Biotechnology, Drug Development, Pharmaceutical, Biopharma, Therapeutics, Next Generation Therapeutics, Innovative Therapeutics, Biopharmaceutical Development, Drug Discovery, Pharmaceutical Research, Precision Medicine, Targeted Therapy, Immunotherapy, Biotechnology Solutions |
| Competitors | Pfizer, Amgen, The Janssen Pharmaceutical Companies of Johnson & Johnson, AstraZeneca, Novartis, Gilead Sciences, Genentech, Regeneron, Moderna Therapeutics, Lilly India +35 more (view full list) |
Looking for a particular VALANX Biotech employee's phone or email?
Michael Lukesch is the CEO and Founder of VALANX Biotech.
14 people are employed at VALANX Biotech.
VALANX Biotech is based in Klosterneuburg, Lower Austria.